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Short telomeres induce a DNA damage response,
senescence, and apoptosis, thus maintaining telo-
mere length equilibrium is essential for cell viability.
Telomerase addition of telomere repeats is tightly
regulated in cells. To probe pathways that regulate
telomere addition, we developed the ADDIT assay
to measure new telomere addition at a single telo-
mere in vivo. Sequence analysis showed telome-
rase-specific addition of repeats onto a new telo-
mere occurred in just 48 hr. Using the ADDIT assay,
we found that ATM is required for addition of new
repeats onto telomeres in mouse cells. Evaluation
of bulk telomeres, in both human and mouse cells,
showed that blocking ATM inhibited telomere elon-
gation. Finally, the activation of ATM through the
inhibition of PARP1 resulted in increased telomere
elongation, supporting the central role of the ATM
pathway in regulating telomere addition. Under-
standing this role of ATM may yield new areas for
possible therapeutic intervention in telomere-medi-
ated disease.
INTRODUCTION
The ATM protein kinase is a central regulator of the cellular
response to DNA damage and the response to telomere
dysfunction. After recognition of damage, ATM signals cell-cycle
arrest and induction of repair pathways (Kastan and Lim, 2000;
Paull, 2015). Ataxia telangiectasia (AT) patients, who lack ATM
function, have immune system defects and neurological impair-
ment and are cancer prone and radiosensitive (Shiloh and Ziv,
2013). A role for ATM in telomere length maintenance was sug-
gested when the ATM gene was cloned (Savitsky et al., 1995)
and shown to be the homolog of the yeast Tel1 gene (Greenwell
et al., 1995). In yeast, loss of Tel1ATM function leads to short telo-
meres. However, there have been conflicting results regarding
the role of ATM in regulating telomere elongation in mammalian
cells. In human cells, a prominent, early paper suggested thatCell RepATM plays no role in human telomere maintenance (Sprung
et al., 1997). However, other reports suggested cells might
have shorter telomeres in the absence of ATM (Metcalfe et al.,
1996; Xia et al., 1996; Vaziri et al., 1997; Hande et al., 2001; Tchir-
kov and Lansdorp, 2003).Modification of human TRF1 protein by
both ATM and tankyrase regulates binding of TRF1 to the telo-
mere, yet this regulation of TRF1 is not conserved in mice (Hsiao
et al., 2006; Wu et al., 2007; Chiang et al., 2008).
Telomere length maintenance is essential for cell viability.
Telomere shortening that occurs during cell division is balanced
by telomerase, which adds telomere repeats onto chromosome
ends (Greider and Blackburn, 1985). The delicate balance of
shortening and lengthening is regulated by an intricate series
of feedback mechanisms that establish a dynamic telomere
length equilibrium (Smogorzewska and de Lange, 2004). In
humans, syndromes of telomere shortening cause age-related
degenerative diseases including dyskeratosis congenita, pulmo-
nary fibrosis, aplastic anemia, and others (Armanios and Black-
burn, 2012). Elucidating the molecular interactions that regulate
telomere elongation is essential to understand telomere function
and how it is disrupted in disease.
At the cellular level, loss of tissue renewal is caused by short
telomeres that activate a DNA damage response, inducing
apoptosis or senescence (Lee et al., 1998; Hao et al., 2005). Crit-
ically short telomeres activate the ATM and ATR kinase-depen-
dent pathways in primary human cells, leading to senescence
(d’Adda di Fagagna et al., 2001). In addition, induction of telomere
dysfunction through the removal of shelterin components also ac-
tivates ATM or ATR-dependent signaling and cell-cycle arrest
(Palm and de Lange, 2008). Cancer cells avoid cell death through
increased telomerase expression or othermechanisms thatmain-
tain telomere length (Greider, 1999; Artandi and DePinho, 2010).
Although, there is a well-established role for ATM and ATR in
signaling telomere dysfunction in human and mouse cells, less
is known about the role of these kinases in normal telomere elon-
gation. In yeast, Tel1ATM and Mec1ATR play partially redundant
roles at telomeres. The loss of Tel1ATM generates short, stable
telomeres, while loss of Mec1ATR alone has no effect. However,
the loss of both Tel1ATM andMec1ATR leads to further shortening
than in Tel1ATM alone (Ritchie et al., 1999). This implies that
Mec1ATRmay partially compensate for the loss of Tel1ATM in telo-
mere maintenance, as discussed in more detail below.orts 13, 1623–1632, November 24, 2015 ª2015 The Authors 1623
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Figure 1. De Novo Telomere Addition Oc-
curs Only in Telomerase-Positive Cells
(A) Schematic of the ADDIT assay. I-Sce1 cutting
at the endonuclease site (green box) exposes the
480-bp telomere seed sequence (orange arrows).
New telomere repeats (lighter orange arrows) are
added by telomerase.
(B) Representation of modified STELA, showing
primers (arrows) and linkers either telorette added
to telomere or IScerette added to cleaved I-Sce1
end. Telomeres were PCR amplified with a HYG-
specific forward primer, either F1 or F2, and a
reverse primer, teltail. S, Sph1.
(C) STELA PCR products, using either F1 or F2
primer, were analyzed by Southern hybridization
using HYG probe (purple bar with asterisk shown
in B).
(D) Analysis of PacBio circular consensus
sequence (CCS) reads. Each horizontal line
represents one CCS read. Wild-type telomere re-
peats are shown in orange, divergent telomeric
sequence in darker orange, and the I-Sce1 site in
green. x axis indicates the length (bp) from the start
of the telomere seed sequence. Amaximum of 400
reads from each sample are shown for simplicity.
(E) Bar graph shows percentage of PacBio CCS
reads with de novo telomere repeats from each
sample. Asterisk indicates p value is <0.05 (n =
number of separate experiments).
(F) The sequences of PacBio CCS reads boxed in
(D) are shown.
See also Figures S1, S2, and S3.To examine the role of ATM in telomere maintenance, we
developed an assay that we term ADDIT (addition of de novo
initiated telomeres), which measures telomere addition at a sin-
gle chromosome end. Using this assay, we demonstrate that
ATM is required for telomere addition. This assay will allow iden-
tification of additional telomere length regulators that may un-
cover other novel approaches to manipulating telomere length
for treatment of disease.
RESULTS
Addition of De Novo Initiated Telomeres: ADDIT Assay
To critically access the role of ATM, aswell as other potential telo-
mere length regulators, we developed an assay that measures
telomere repeat addition in cells over 48 hr. We engineered a
CAST/EiJ mouse fibroblast cell line (SL13) containing a condi-
tional mTR allele and a modified chromosome 4 (chr4) with an
internal 480-bp telomere ‘‘seed’’ sequence followed by a unique
I-Sce1 endonuclease cut site (Figure S1; see Experimental Proce-
dures). The internal telomere seed sequence can be conditionally1624 Cell Reports 13, 1623–1632, November 24, 2015 ª2015 The Authorsexposed by I-Sce1 endonuclease cleav-
age (Figure 1A) and then be elongated
by telomerase in a manner similar to de
novo telomere addition shown to occur in
yeast (Diede and Gottschling, 1999).
Expression of doxycycline-inducible
HA-tagged I-Sce1 endonuclease in thisSL13 cell line exposed the telomere seed and allowed telomere
addition by telomerase (Figures 1C and S1C). Chromosome cut-
ting occurred by 8 hr after doxycycline treatment (Figure S1D).
As a control, we isolated genomic DNA and digested it in vitro
with purified I-Sce1 endonuclease to compare the in vivo and
in vitro cut DNA on a Southern blot. At 36 and 48 hr, a ‘‘smear’’
above the in vivo cut telomere seed band was detected faintly
on the Southern and suggested some de novo telomere addition
(Figure S1D).
To better detect the telomere elongation, wemodified the single
telomere lengthanalysis (STELA) assay (Baird et al., 2004), tomea-
sure telomere length at the in vivo cut chr4. We ligated the linker,
‘‘telorette,’’ to the telomere and PCR amplified the telomere using
the ‘‘teltail’’ primer and an internal primer in the hygromycin resis-
tance (HYG)sequenceontheengineeredchromosome(Figure1B).
To determine the un-extended cut chromosome length in vitro,
we designed a different linker, ‘‘IScerette,’’ which anneals to the
4-nt 30 overhang created by the I-Sce1 endonuclease (Figure 1B).
PCR using the forward primers, F1 or F2, and the teltail generated
products of predicted size on a Southern blot (Figure 1C).
To examine whether elongation was telomerase dependent,
we deletedmTR by Flp recombinase to generatemTR– cells (Fig-
ures S1E and S1F) and carried out the ADDIT assay. The STELA
PCR products in the mTR– cells treated with doxycycline were
similar to and shorter than the control IScerette in vitro cut
DNA, likely because of in vivo resection by nucleases. In
contrast, the STELA products from mTR+ cells were longer
than the control IScerette products (Figure 1C), suggesting
new telomeric sequence was added. Together, these data sug-
gest the longer products in mTR+ cells are the result of telome-
rase elongation of the seed sequence in vivo.
Sequence Analysis of the Telomere Addition Products
To further verify telomere addition had occurred, we sequenced
the PCR products with Pacific Biosciences (PacBio) sequencing.
PacBio produces long sequence reads (Loomis et al., 2013) that
allowed us to determine telomere length. While sequencing er-
rors, predominantly point insertions and deletions, occurred as
expected (Carneiro et al., 2012), the telomere repeats were easily
recognizable. To assure products were full length, we filtered the
PacBio reads to examine only those that had the unique HYG
sequence followed by the seed telomere repeat sequence and
also had the teltail primer sequence (Figure S2). Individual reads
are displayed as a horizontal line, where the wild-type TTAGGG
repeats are colored orange and variant telomere repeats are
colored in darker orange. The I-Sce1 site is shown in green (Fig-
ure 1D). We noted three regions of variant telomere repeats,
evident as darker orange stripes in the aligned reads, that were
present in the original SL13 clone and served as useful sequence
reference points (Figure 1D). If therewere degradation past these
variants and then new TTAGGG repeat synthesis in vivo, these
landmarks would be removed.
The PacBio sequence reads from the mTR+ sample showed a
heterogeneous population of telomere lengths and notably had a
significant fraction of telomeric reads that contained the I-Sce1
cut site followed by additional telomere sequences (Figures 1D
and 1F). Telomerase will add telomere repeats onto primers (or
sequences) that contain some non-telomeric sequence (Greider,
1991; Harrington and Greider, 1991; Morin, 1991; Kramer and
Haber, 1993) as described below. A number of reads were
shorter than the reference sequence and likely arose from
50-end resection occurring in vivo at telomeres that were not
elongated. The mTR– samples showed only resection, and the
I-Sce1 site was not present. We defined telomerase addition
as occurring when telomere sequence was added onto the
I-Sce1 site. There were a few longer reads in the mTR– cells;
however, these did not have telomere addition beyond the
I-Sce1 site, suggesting these longer products occurred through
slippage during STELA PCR and/or the PacBio sequencing.
The sequence lengthdistribution in theADDITassay represents
telomere elongation, incomplete telomere replication, and in vivo
end resection (as well as PacBio sequencing errors). To examine
the telomerase interactionat the telomere,wequantitated theper-
centage of reads that showed elongation past I-Sce1, which rep-
resents telomerase recruitment to the telomere. In themTR+ cells,
around 20%of the reads had telomere sequence after the I-Sce1
site representing de novo addition, while the mTR– sample
showed no addition of repeats beyond the I-Sce1 site (Figure 1E).Cell RepIn an additional control, small interfering RNA (siRNA) against
TERT also blocked repeat addition beyond the I-Sce1 site (Fig-
ure S3). As expected, sequence reads from the in vitro IScerette
control sample showed no elongation (Figures 1D and 1E). The
small changes in length and sequence in this sample likely repre-
sent the PacBio sequencing errors or slippage during PCR.
De Novo Telomere Addition onto I-Sce1 Site
We examined the sequence reads to determine how telomerase
added repeats to the I-Sce1 site. During telomere elongation, the
RNA component of telomerase, mTR, anneals to the telomere
through the primer-alignment region and uses the template re-
gion to add telomere repeats (Autexier and Greider, 1995). For
the mouse telomerase RNA, there is a 2-nt alignment region,
while the human RNA contains 5 nt in the alignment region
(Chen and Greider, 2003a, 2003b). Evaluation of the I-Sce1
cleavage site showed that it has sequence complementarity to
the mTR primer-alignment region (Figure 2A).
The sequence junction between the I-Sce1 site and the de
novo telomere repeats defined six different elongation classes,
which have unique base-pairing of the 30 end of the I-Sce1 site
with the mTR (Figure 2B). In class 1, 205 of the 1,514 (13.5%)
PacBio reads showed telomeric repeats directly added after
the I-Sce1 30 overhang without any loss of nucleotides (Fig-
ure 2B). The most common class of telomere addition, class 3
(48.0%) had loss of 4 nt from the I-Sce1 site, creating the most
complementarity (AGGG) between the 30 end and the mTR
sequence. The next most common class 5 (15.3%) resulted
from base-pairing a G-rich sequence internal to the cleavage
site forming three G:C base pairs. Interestingly, in class 2, the
30 end resection positions the de novo 30 end within the align-
ment region of mTR and resulted in the incorporation of a C at
the junction with the telomere repeats that is present in neither
the I-Sce1 site nor the telomere sequence. Incorporation of a
sequence in the alignment region has also been seen in vitro
(Autexier and Greider, 1995) and provides further evidence that
telomere repeats are added by telomerase activity.
ATM Kinase Is Essential for Telomere Addition
To probe the role of ATM, we used the ADDIT assay in cells
treated with the ATM-specific inhibitor KU55933 (Hickson
et al., 2004) or with siRNA to ATM. To confirm the inhibition of
ATM, we examined the phosphorylation level of the ATM sub-
strate Kap1 and, as a control, an ATR kinase substrate Chk1
by western blot. Cultured cells were pretreated with KU55933,
siATM, or DMSO control and then exposed to camptothecin
(CPT), a DNA damaging agent. Western blot analysis with anti-
bodies to the phosphorylated Kap1-S824 and Chk1-S345 indi-
cated that KU55933 and siATM blocked Kap1 phosphorylation
but not Chk1 phosphorylation (Figures 3A and 3B). This indicated
that both KU55933 and siATM specifically inhibited ATM
signaling, without affecting the ATR pathway.
PacBio sequencing of the ADDIT assay products indicated
de novo telomere repeat addition beyond the I-Sce1 site was
significantly reduced in three separate experiments when ATM
was knocked downwith siRNA (Figures 3C and 3D). Cells treated
with the KU55933 had significantly fewer telomere elongation
products compared to controls in replicated experimentsorts 13, 1623–1632, November 24, 2015 ª2015 The Authors 1625
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Figure 2. Classification of De Novo Telo-
mere Addition
(A) The 42-nt unique sequence (green) located
immediately after telomere seed includes the 18-nt
I-Sce1 recognition site (black box). I-Sce1 cutting
leaves a 30 4-nt overhang. The sequences of the
telomerase mTR template (blue) and primer-
alignment region (red) are shown. Potential Wat-
son-Crick base-pairings indicated by vertical lines.
Wobble pairing shown with dotted vertical lines.
(B) A total of 1,514 PacBio CCS reads from wild-
type samples were classified by where the telo-
mere repeat sequences were added, and the
percentage of reads in each class are shown in
parentheses. The different degree of 30 end
resection of the I-Sce1 site and potential posi-
tioning with mTR primer region is shown alongwith
a representative PacBio read of each class. The
incorporation of a C residue in class 2 is high-
lighted in yellow. De novo added wild-type telo-
mere repeats are in pink.
See also Table S1.(two-tailed p value = 0.03, t test). These results indicate that
blocking ATM activity prevents telomerase-mediated de novo
telomere repeat addition. The difference in the pharmacologic in-
hibition of ATM with KU55933 and the siRNA knockdown might
be due to the presence or absence of the ATM protein itself (Ma
and Greider, 2009) or a dominant effect of blocking ATM. Inter-
estingly, expression of a kinase dead ATM is lethal in mice while
ATM deletion is viable yet radiosensitive (Barlow et al., 1996;
Daniel et al., 2012; Yamamoto et al., 2012).
To determine whether ATM inhibition altered the mechanism
of telomerase elongation, we examined the distribution of the
six different classes of elongation products described in Figure 2.
Although there was some variability in the distribution of prod-
ucts (Table S1), the most dominant class of telomere addition
was class 3 that creates the most complementarity between
the 30 end and the mTR sequence, suggesting that telomerase
action is intact, but its recruitment is impaired by the loss of ATM.
To further define the role of ATM in telomere elongation, we
overexpressed telomerase. Overexpression of telomerase in
immortal cultured cells results in excessive telomere elongation
(Cristofari and Lingner, 2006). We treated SL13 cells with either
KU55933 or the ATR inhibitor VE821 (Reaper et al., 2011) and
transduced them with a lentivirus expressing both mTR and
mTERT. Controls showed the specificity of VE821 (Figure S4A).
Telomere lengths examined on Southern blots showed rapid
elongation in control cells as early as day 6. However, treatment1626 Cell Reports 13, 1623–1632, November 24, 2015 ª2015 The Authorswith the ATM inhibitor KU55933 blocked
this telomere elongation (Figure 4A).
Cells treated with the ATR inhibitor
VE821 showed subtle but reproducible
decreased elongation at day 6, although
the effect was not as great as with ATM in-
hibition (Figure 4A). Taken together, the
results from the ADDIT assay and the
Southern data indicate that ATM kinase
is required for telomere elongation by telo-merase. ATR may also play a role in telomere length regulation,
though not to the same extent as ATM.
Inhibition of ATM Kinase Shortens Telomeres in Human
Cells
ATM has been proposed to play different roles in signaling telo-
mere dysfunction in human and mouse cells (Smogorzewska
and de Lange, 2002). Since it is not yet clear whether the damage
signaling is mechanistically linked to telomere elongation, and
given the discrepant reports of the role of ATM in human telo-
mere length (Metcalfe et al., 1996; Xia et al., 1996; Sprung
et al., 1997; Vaziri et al., 1997; Hande et al., 2001; Tchirkov and
Lansdorp, 2003), we wanted to revisit the role of ATM in human
cells. KU55933 shortens bulk telomeres in HT1080 cells (Wu
et al., 2007), and we also found telomere shortening in human
HCT116 (Figure 4B). When the mouse cell line SL13 was grown
in KU55933, telomere shortening also occurred, although at a
somewhat slower rate (Figure 4C); however, this shortening
was reproducible (Figures S4B and S4C).
Activation of ATMKinase Pathway Elongates Telomeres
To further probe the role of ATM in telomere length, we sought to
activate ATM in cultured cells. Cells treated with an inhibitor of
poly (ADP-ribose) polymerase 1 (PARP1) were shown to activate
ATM (Bryant and Helleday, 2006; Wahlberg et al., 2012). PARP is
an essential enzyme involved in recognition and repair of DNA
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Figure 3. ATM Kinase Is Required for Telo-
mere Addition
(A) Western blot analysis of SL13 cells pretreated
with either 10 mM KU55933 or DMSO and then
exposed to 10 mM CPT for 4 hr. After immuno-
blotting with anti-phospho-Kap1 (S824) and anti-
Actin antibodies, the blot was stripped and re-
probed with anti-phospho-CHK1 (S345).
(B) Western blot analysis of SL13 cells pretreated
with either increasing concentration of siATM
(5 nM, 10 nM, 100 nM) or DMSO and then exposed
to 10 mM CPT for 4 hr (top). Relative expression
levels of phosphorylated Kap1-S824 normalized
to Actin are the following from left to right: 0.03,
1.00, 0.64, 0.46, 0.22. In the bottom blot, a final
concentration of 100 nM of siATM was used. After
immunoblotting with anti-phospho-CHK1 (S345),
the blot was stripped and re-probed with anti-
Actin antibody.
(C) Representative analysis of PacBio CCS reads
(maximum of 200 shown for simplicity) from sam-
ples pretreated with DMSO, 10 mM KU55933, or
100 nM siATM prior to doxycycline treatment.
(D) Bar graph shows percentage of CCS reads
with de novo telomere addition. The means and
SEM from multiple experiments (n) are the
following: 19.56 ± 2.06 for DMSO, 12.45 ± 1.16 for
KU55933, and 0 ± 0 for siATM. Asterisk indicates
unpaired t test two-tailed p value is <0.05.breaks.We treated cells with the PARP1 inhibitor, Olaparib (Fong
et al., 2009), and also found that PARP1 inhibition correlated with
increased ATM phosphorylation of Kap1 and increased phos-
phorylation of ATM-S1981 (Figure 5A). Using the ADDIT assay,
we found the percentages of elongated telomeres were signifi-
cantly increased in cells treated with Olaparib compared to
controls, from 20% to 26%, in five independent experiments
(two-tailed p value = 0.03, t test) (Figures 5C and 5D). Similar to
wild-type control, the most common class of telomere addition
was class 3 that creates the most complementarity between
the 30 endand themTRsequence (TableS1). To examinewhether
this stimulation of telomere elongation acts through ATM, we
examined epistasis by treating cells with both Olaparib and
KU55933. Co-treatment significantly reduced telomere addition
compared to Olaparib only (p value = 0.04, t test) (Figures 5C
and 5D), suggesting the increased telomere elongation by Ola-
parib treatment acts, at least in part, through the ATM pathway.
As an independent test of Olaparib on telomere length, we
examined telomeres by Southern blot in cultured SL13 cells
grown in the presence of Olaparib for an extended time. Telo-
mere length gradually increased in the presence of Olaparib
over the course of the experiment (Figure 5B). Taken together,
the experiments described here indicate that inhibition of ATM
blocks telomere elongation, whereas activation of ATM stimu-
lates telomere elongation.
Telomerase is known to be phosphorylated (Kang et al., 1999),
so we wanted to examine whether the KU55933 or Olaparib
treatment of cells might directly affect telomerase activity. We
measured telomerase activity by a quantitative direct activity
assay (Nandakumar et al., 2012) in human cells treated withCell RepKU55933 or Olaparib and found no change in telomerase activity
(Figure 6). We conclude that ATM kinase is a positive regulator of
telomere elongation in bothmouse and human cells, and that the
effects of ATM inhibition are not due to inhibition of telomerase
enzyme activity.
DISCUSSION
The ADDIT assay provides a powerful tool to examine elongation
of a single chromosome end over just one or two cell cycles.
Using this assay, we showed that blocking ATM activity led to
decreased telomere elongation, while activation of ATM by Ola-
parib increased telomere elongation. Further, Southern blots
validated that inhibition of ATM shortens telomere in both human
andmouse cells. The ADDIT assay may allow rapid identification
of new regulators of telomere length, as even essential genes
can be examined since long-term growth is not required.
Conservation of the Role of ATM in DNA Damage and at
Telomeres
The role we propose for ATM in stimulating telomere elongation
parallels its role in DNA damage. When DNA breaks are encoun-
tered, ATM phosphorylates specific mediator proteins such
Chk2 and p53 that arrest the cell cycle and also activate DNA
repair pathways (Shiloh and Ziv, 2013). If there is extensive
DNA damage that cannot be repaired, cells undergo either
apoptosis or cellular senescence. The role of ATM in signaling
telomere dysfunction is well established (Karlseder et al., 1999;
d’Adda di Fagagna et al., 2003; de Lange, 2009). Here, we link
ATM signaling to telomere elongation; we propose that telomereorts 13, 1623–1632, November 24, 2015 ª2015 The Authors 1627
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Figure 4. ATM Is Essential for Bulk Telomere Elongation in Both
Human and Mouse Cells
(A) Telomere Southern blot of SL13 cells treated with DMSO, 10 mMKU55933,
or 5 mMVE821 and then transduced with a lentivirus expressing both mTR and
mTERT (mTR/mTERT) and grown for 1, 6, and 9 days.
(B) Telomere Southern blot of HCT116 cells treated with 10 mM KU55933 and
examined at different population doublings (PD).
(C) Representative telomere Southern blot of SL13 cells treated with 10 mM
KU55933.
See also Figure S4.elongation is a form of ongoing repair that prevents telomeres
from becoming critically short.
The decrease in telomere length when ATM was inhibited was
not due to a decrease in telomerase enzyme activity. Our results
are consistent with results in S. cerevisiae where the loss of
Tel1ATM causes telomere shortening, but telomerase enzyme ac-
tivity was not affected (Chan et al., 2001). Elegant work in
S. pombehas shown that phosphorylationof the telomerebinding
protein Ccq1 by the ATM and ATR kinases allows Est1 to recruit
telomerase to the telomere (Moser et al., 2011; Yamazaki et al.,
2012). While specific ATM substrates that affect telomere length
in S. cerevisiae and mammalian cells are still not fully known,
ATM phosphorylates TRF1, which mediates telomere elongation1628 Cell Reports 13, 1623–1632, November 24, 2015 ª2015 The Au(Wu et al., 2007), and other substrates may also play a role. In
this issue of Cell Reports, Tong et al. (2015) also show that ATM
regulates telomerase access to telomeres and find that TRF1
plays a role in that process.
ATR May Compensate for Loss of ATM
ATM and ATRmay have partially redundant functions in telomere
length maintenance in mammals as they do in yeast. In
S. cerevisiae, Mec1ATR plays a minor, yet critical role in telomere
maintenance (Ritchie et al., 1999). Cells lacking Tel1ATM are
completely defective in telomere extension in a de novo addition
assay (Frank et al., 2006;MaandGreider, 2009), yet bulk telomere
lengths of tel1ATMD cells are not as short as tel1ATMDmec1ATRD
cells (Ritchie et al., 1999). Interestingly, in S. pombe, the role of
the two genes seems to be reversed (Nakamura et al., 2002).
The rad3ATR mutant cells have much shorter telomere lengths
compared to tel1ATM mutants, although like in S. cerevisiae, the
double mutants have even shorter telomeres (Naito et al., 1998).
Our previous work in mice showed that ATM is not required for
rescue of the shortest telomeres in an intergenerational cross
(Feldser et al., 2006). When ATM+/ mice were crossed to
ATM+/+ mTR/ G5 late generation mice with short telomeres,
the F1 progeny showed rescue of signal free ends in both
ATM+/+ mTR+/ and ATM/ mTR+/ genotypes. We concluded
in that study that ATM is not essential for elongation of the short-
est telomeres. Our current work indicates ATM does play an
important role; however, ATRmay still play some role in telomere
elongation. Perhaps in the earlier study the rescue of short ends
(Feldser et al., 2006) was due to ATR compensating for the loss
of ATM during the many cell divisions that occurred from one
generation to the next in this animal model. The role of the ATR
kinase on telomere length in mice in vivo has not been examined,
as ATR-null mice are not viable.
Activation of ATM Leads to Telomere Elongation
Understanding the pathways that regulate telomere elongation
will allow future pharmacological manipulation of telomere
length. Here, we showed that one method that activates ATM,
PARP inhibition (Bryant and Helleday, 2006; Wahlberg et al.,
2012), can lead to increased telomere length. The PARP inhibitor
Olaparib is FDA approved for the treatment of ovarian cancer,
although its side effects make it an unlikely candidate for telo-
mere elongation in vivo (Fong et al., 2009; Banerjee et al.,
2010; Kim et al., 2015). PARP inhibition blocks the repair of dou-
ble-stranded DNA breaks, and, in cells that are already deficient
for BRCA1/2, PARP inhibition leads to synthetic lethality (Under-
hill et al., 2011). The mechanism for increased ATM activity with
Olaparib treatment might be by increasing double-strand DNA
breaks in cells and thus sending increased DNA damage signal,
or might operate through some other mechanism.
The effects of PARP1 inhibitors may have different conse-
quences in mice and humans. Our preliminary experiments with
Olaparib treatment in human cells showed no alteration in telo-
mere length (datanot shown). Inhumans, tankyrase1and2,mem-
bers of PARP family, positively affect telomere length through the
ADP ribosylation of TRF1 (Cook et al., 2002; Seimiya and Smith,
2002). However, the sites for ADP ribosylation are not conserved
in mouse tankyrase (Hsiao et al., 2006; Chiang et al., 2008).thors
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Figure 5. Activation of ATMKinase Pathway
Elongates Telomeres
(A) Western blot analysis of SL13 cells treated with
either DMSO or Olaparib at final concentration 1,
3, 5, or 10 mM for 24 hr. After immunoblotting with
anti-PAR and anti-Actin antibodies, the blot was
stripped and re-probed with anti-phospho-Kap1
(S824). The same lysates were also analyzed
with anti-phospho-ATM (S1981) and anti-Actin
antibodies.
(B) Telomere Southern blot of SL13 cells treated
with 3 mM Olaparib and examined at different
population doublings (PD).
(C) Representative analysis of PacBio CCS reads
(maximum of 350 reads shown for simplicity).
Samples were pre-treated with DMSO (as control)
or either 10 mM KU55933 or 3 mMOlaparib or both
10 mM KU55933 and 3 mM Olaparib prior to
doxycycline treatment.
(D) The mean percentages and SEM of CCS reads
with de novo telomere addition from multiple ex-
periments (n) are the following: 19.2 ± 2.06 for
DMSO, 12.45 ± 1.16 for KU55933, 26.1 ± 1.19 for
Olaparib, and 15.33 ± 5.88 for Olaparib and
KU55933. Asterisk indicates unpaired t test one-
or two-tailed p value is <0.05.In vitro assays indicate that PARP1 inhibitors, including Olaparib,
are highly specific to PARP1-4 and have little effect on tankyrases
(Wahlberg et al., 2012). However, it will be important to verify
whether these drugs affect tankyrase activity to understand their
potential effects on telomere length regulation in humans.
The PARP activation of ATM shows that in principle one can
pharmacologically manipulate telomere length. As we probe
the many nodes in the ATM pathway for their effect on telomere
length more deeply, we, and others, can develop more sophisti-
cated methods to modulate telomere length as possible treat-
ments of disease. Ultimately, finding a safe way to elongate telo-
meres may benefit individuals with short telomere syndromes.
EXPERIMENTAL PROCEDURES
Plasmid Construction
Plasmid construction strategies are described in the Supplemental Experi-
mental Procedures. Primers used are listed in Table S2.
Generation of SL13 Cell Line
Togenerate the telomerase-conditional cell line,mTR/ skin fibroblast cell line
from CAST/EiJ mice (Morrish and Greider, 2009) were transduced with a retro-
virus (plSL8) containingmTRand the green fluorescence protein (GFP) that can
be removed by FLP/FRT recombination and flow sorted for GFP-positive fluo-
rescence (Figure S1E). In the chromosomally stable GFP-positive cells, we
modified chromosome 4 (chr4) to generate an internal 480-bp telomereCell Reports 13, 1623–1632, No‘‘seed’’ sequence followed by a unique I-Sce1
endonuclease cut site (Figure S1A). The length of
seed sequence was based on an early study
showing that 400 bp of telomere repeats can act
as a functional telomere (Farr et al., 1991). In brief,
cells were transfected with linearized chr4 target-
ing construct (plSL25) using XtremeGENE 9
(Roche). After 3 days of transfection, cells were
selected for hygromycin resistance at final concen-tration of 500 mg/ml for 1 week followed by an additional 1 week of negative
selection with ganciclovir at 35 mg/ml final concentration to select against Tk
gene. The HYGRGVCR cells were plated at a very low density and grown for
approximately 2weeks until clonal populationswere visible. Clonal populations
were isolated with cloning cylinders (Sigma, #C1059) and screened for correct
integration by Southern analysis. We identified two independent HYGR clones,
clone termed 1L and 1M, each containing a single chr4 allele that was correctly
modified (FigureS1B). Tocut theendogenouschromosome4at theengineered
I-Sce1 site in vivo, we stably integrated a HA epitope tagged I-Sce1 endonu-
cleasedrivenbya tetracycline-inducible promoter (plSL39), and laterRFP-pos-
itive cells were flow sorted in 96-well plate as single clones. To induce I-Sce1
expression, doxycycline at final concentration of 2 mg/ml was added to cells.
Typically, cells were collected post 48 hr of doxcycline treatment.We identified
a clone (SL13) that expressedHA-I-Sce1 only in thepresence of doxycycline by
western blot (Figure S1C). To compare telomere addition in cells with and
without telomerase, SL13 cells were transfected with a construct expressing
the flp recombinase (pPGKFLPobpA, Addgene #13793). Approximately
10 days later, flow cytometry was used to sort GFP-positive (with mTR) and
GFP-negative (without mTR) cells. We measured mTR level by qRT-PCR and
confirmed mTR was present in GFP-positive cells but absent in GFP-negative
cells (FigureS1F).We refer to thesepopulations asmTR+ormTR–, respectively.
Cell Culture and Treatments
Cell lineswere grown inDMEM (GIBCO) supplementedwith 1%penicillin/strep-
tomycin/glutamine (PSG) and10%heat-inactivatedFBS (Invitrogen). SL13 cells
weregrown inDMEM(GIBCO)supplementedwith1%PSGand10%Tet system
approved FBS (Clontech, #631107). Cells were treated with ATM inhibitor
KU55933 (R&D Systems, #3544), ATR inhibitor VE821 (Selleckchem, #S8007)vember 24, 2015 ª2015 The Authors 1629
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Figure 6. Telomerase Activity Is Unaffected
by Either Olaparib or KU55933 Treatment
(A) Western blot analysis of 293TREx-0611 cells
pretreated with either DMSO or 20 or 30 mM
KU55933 and then exposed to 10 mMCPT for 4 hr.
Immunoblotted with anti-phospho-Kap1 (S824)
and anti-Actin antibodies.
(B) Western blot analysis of 293TREx-0611 cells
treated with either DMSO or Olaparib at final con-
centration 0.5, 1, 3, or 5 mM. Immunoblotted with
anti-PAR and anti-Actin antibodies.
(C) Direct telomerase activity assay usingwhole cell
lysates from 293TREx-0611 cells expressing
hTERT, hPot1, and hTTP1 that were transfected
with hTRovernight and treatedwithDMSOor 30mM
KU55933. Reactions were stopped at 10 or 15min.
End-labeled 18-mer loading control (LC), RNaseA-
treated control (RNaseA), and numbers of telomere
repeats added to 18-mer primer are indicated.
(D) Direct telomerase activity assay using lysates
from cells treated with DMSO or 5 mM Olaparib.orPARP1 inhibitorOlaparib (Selleckchem, #1060) at indicated concentrationsor
DMSO as a control. For the ADDIT assay, SL13 cells were treatedwith final con-
centration 2 mg/ml of doxycycline for typically 48 hr or as indicated.
Modified Single Telomere Length Analysis for Mouse chr4
The original single telomere length analysis (STELA) protocol used for human
cells (Baird et al., 2004) was modified to measure telomere lengths on the cut
end of chr4 in SL13 cells. Briefly, genomic DNA was extracted using Puregene
Core Kit A (QIAGEN). Then, 4 mg of genomic DNAwas digested with SphI (NEB)
and later diluted to 10 ng/ml in water. For the in vitro IScerette sample, genomic
DNA was digested with SphI and I-SceI (NEB) prior to ligation. The ligation was
carried out at 35C for at least 12 hr in a volume of 10 ml containing 10 ng of1630 Cell Reports 13, 1623–1632, November 24, 2015 ª2015 The Authorsdigested genomic DNA, 0.9 mM of telorette linkers
or IScerette linker and 0.5 U of T4 DNA ligase
(NEB) in 13 T4 ligation buffer. Multiple PCRs (typi-
cally 24 or 32 reactions per sample) were carried
out for each sample in 25 ml containing 1 ng of
ligated DNA, 0.2 mM HYG-specific and teltail
primers, 1 3 Fail Safe PCR buffer H (Epicenter
FSP995H), 1 U of Fail Safe Enzyme Mix (Epicenter
FS99100). The PCRs were pooled for each sample
and purified using magnetic beads (Agencourt
AMPure XP, Beckman Coulter). An equal fraction
from each sample was analyzed by Southern blot
using a HYG probe (see the Supplemental Experi-
mental Procedures).
PacBio Sequence Reads Analysis
We created a pipeline in R (see Figure S2) that an-
alyzes PacBio sequencing data generated from
modified STELA. The percentage of PacBio CCS
reads with de novo telomere repeats are calculated
from each sample by using the following formula:
100% 3 [(number of CCS reads with telomere re-
peats added beyond the I-Sce1 site) / (number of
total CCS reads)]. Unpaired t test generated the
one- or two-tailed p values.
siRNA-Mediated Knockdown of ATM and
TERT
ON-TARGET siRNA SMART pools fromGE Health-
care were used: mouse TERT (L-048320-01-0005),mouse ATM (11920). SL13 cells were transfected using Pepmute protocol
(SignaGen Lab). The final concentration of siRNAs was 5100 nM for each
transfection. The efficiency of knockdown for each siRNA was assessed by
immunoblotting or qRT-PCR.
Direct Telomerase Activity Assay
Telomerase activity was assayed in whole-cell lysates with a modified
protocol (Nandakumar et al., 2012). 293TREx-0611 cells overexpressing
TPP1, POT1, and hTERT were seeded (3 3 105 cells) per well in a poly-D-
lysine-coated 6-well plate. The next day, cells were transfected with U1-hTR
using Lipofectamine 3000 and incubated overnight. Then, they were treated
with 30 mM KU55933, 5 mM Olaparib, or DMSO for 2 hr before harvesting in
100 ml 1 3 CHAPS. Cells were lysed on ice for 30 min, vortexing occasionally,
and cleared by spinning (8,000 rpm, 20 min, 4C). For negative controls, 25 ml
cleared lysate was incubated at 65C with 1 ml RNaseA (1 mg/ml) for 10 min.
For direct telomerase assays, lysates were incubated with primer a5 (Wang
et al., 2007) in 1 3 telomerase buffer (50 mM Tris-Cl, 30 mM KCl, 1 mM
MgCl2, 1 mM spermidine), 0.5 mM dTTP, 0.5 mM dATP, 2.92 mM dGTP, and
0.33 mM a32P-dGTP at 30C. Reactions were stopped at 10 or 15 min with
20 mM EDTA, 10 mM Tris spiked with 500 cpm end-labeled 18-mer. Telome-
rase products were purified by phenol chloroform extraction, ethanol precipi-
tated, washed with 70% ethanol, and resuspended in 5 ml water and 5 ml 2 3
formamide loading dye. Products were denatured at 100C and separated on
a sequencing gel (10% acrylamide, 7 M urea 13 TBE), at 90 W for 1.5 hr. The
gel was dried, exposed to a phosphor screen overnight and imaged using the
STORM phosphoimager.
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